Author

Wendy A. Hudson

Masonic Cancer CenterORCID 0009-0007-7977-3549Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Alex T. LarssoniD· 2 shared David A. LargaespadaiD· 2 shared Tyler A. JubenvilleiD· 2 shared Adam J. DupuyiD· 1 shared Adam L. BurrackiD· 1 shared Alexander K. TsaiiD· 1 shared Branden S. MoriarityiD· 1 shared Brooke L. KimballiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Alex T. LarssonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyJournal for ImmunoTherapy of CancerPeer-reviewedJul 1, 2026

Sleeping Beauty mutagenesis identifies BACH2 and other regulators of CD8+T cell exhaustion, persistence in vivo, and CAR-T function under tumor-associated chronic antigen stimulation

Chang-Jung Lee, Alex T. Larsson, Tyler A. Jubenville…·David A. Largaespada

The paper uses Sleeping Beauty mutagenesis to identify BACH2 and other genes that enhance CD8+ T cell persistence and function under chronic antigen stimulation, improving engineered T cell therapies.

1 citation

mousescRNA-seq

𝕏 PostBluesky

Cancer BiologyMolecular Cancer TherapeuticsPeer-reviewedOct 1, 2025

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors

Kyle Brandon Williams, Alex T. Larsson, Bryant J. Keller…·David A. Largaespada

This study identifies 23 compounds that selectively kill NF1-deficient Schwann cells and shows their efficacy in vivo, with synergy when combined with Selumetinib.

11 citationstop 5%

humanexperimental assay

𝕏 PostBluesky